Literature DB >> 12216016

Dimensional structure of the Frankfurt Complaint Questionnaire.

Gwenolé Loas1, Valérie Yon, Denis Brien.   

Abstract

The Frankfurt Complaint Questionnaire (FCQ) was designed to evaluate the subjective symptoms of schizophrenics. Several validation studies of the FCQ using principal components analyses (PCA) have shown one-, two-, or four-factor solutions. The present study was conducted using FCQ data on 310 schizophrenics who met the ICD-10 criteria for F20 (schizophrenia) disorder. Using several guidelines to select the number of factors, the PCA yielded one factor. This result suggests a unidimensionality underlying FCQ items. A new scale comprising 24 items was derived from those items with higher weights in the first factor. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Year:  2002        PMID: 12216016     DOI: 10.1053/comp.2002.33487

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  3 in total

1.  The Frankfurt Complaint Questionnaire for self-assessment of basic symptoms in the early detection of psychosis-Factor structure, reliability, and predictive validity.

Authors:  Martina Uttinger; Erich Studerus; Sarah Ittig; Ulrike Heitz; Frauke Schultze-Lutter; Anita Riecher-Rössler
Journal:  Int J Methods Psychiatr Res       Date:  2017-12-21       Impact factor: 4.035

2.  Assessment of cognitive impairment in psychosis spectrum disorders through self-reported and interview-based measures.

Authors:  Ana M Sánchez-Torres; Lucía Moreno-Izco; Gustavo J Gil-Berrozpe; Ruth Lorente-Omeñaca; María Zandio; Amalia Zarzuela; Victor Peralta; Manuel J Cuesta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-04-01       Impact factor: 5.760

3.  Subjective Symptoms in Euthymic Bipolar Disorder and Remitted Schizophrenia Patients: A Comparative Study.

Authors:  Manish Kumar; Vinod Kumar Sinha; Anwesha Mondal
Journal:  Indian J Psychol Med       Date:  2016 Mar-Apr
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.